Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial The model included current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback